CJC-1295 (with DAC)

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal the hypothalamus uses to tell the pituitary gland to release growth hormone. The “with DAC” version includes a Drug Affinity Complex modification — a small chemical addition that causes the molecule to bind to albumin, a protein that circulates in blood.

Proposed Mechanism

Binds circulating albumin through its DAC modification, extending its half-life to roughly a week and producing sustained GH/IGF-1 elevation, in contrast to the short pulse produced by native GHRH.

Research Context

Binding to albumin is the specific research interest here: it protects the peptide from being broken down quickly, extending its functional half-life from minutes (for native GHRH) to roughly a week. Research has focused on whether this sustained exposure produces a steadier elevation in growth hormone and IGF-1 levels compared to the brief pulses produced by unmodified GHRH.

Evidence Status — Well-documented

Well-documented pharmacokinetic and hormonal-response data from human research.

Pharmacokinetic data — how the compound behaves and persists in the body — is reasonably well documented in human research literature. This is a case where the mechanism and behavior of the molecule are well-characterized, even though it is one compound among a broader class of GHRH-axis peptides.

Research Use Only

This page is a scientific reference summarizing publicly available research literature. It contains no dosing, administration, or protocol guidance, and nothing here constitutes medical advice. BactoCore does not sell this or any peptide referenced in this index — the only product sold directly is bacteriostatic water. See the Safety section for who should not handle research compounds, and the Research Use Disclaimer for full terms.